Pfizer and Merck are each scheduled to release their second-quarter financial results early Tuesday. These are just a couple of the Dow Jones industrials that are reporting this week, but they make…
Mylan released its second-quarter financial results before the markets opened on Monday. The pharma giant also announced a major update to its business involving Pfizer and that CEO Heather Bresch is resigning.
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week, including Apple, Exxon and Pfizer.
The Dow Jones industrial average in an all-time high territory, and a lot of experts believe it has room to run. But one particular stock is not helping.
The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
As of the most recently reported period, short sellers favored Intel, Pfizer and Microsoft above all other Dow stocks.
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
Here are five solid defensive picks for investors in what is a very expensive market, and they are also under-owned by active fund managers. All are rated Buy at Merrill Lynch.
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in young children with mild to moderate atopic dermatitis, also known as eczema.
Chris Lange Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Pfizer, Intel and Cisco above all other Dow stocks.
